Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 5/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186097 | 0.88 | L3MBTL1 (0.70) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL16624341 | 0.88 | KDM4E (0.64) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL16624103 | 0.84 | BAZ2B (0.51) | CHRNA7L3MBTL1HTR6BAZ2BGAA | |
| SCHEMBL15977201 | 0.84 | L3MBTL1 (0.76) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL168351 | 0.82 | CHRNA7 (0.64) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL27099161 | 0.82 | CHRNA7 (0.64) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL2190105 | 0.82 | L3MBTL1 (0.61) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL2190132 | 0.82 | CHRNA7 (0.59) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL167846 | 0.81 | CHRNA7 (0.62) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 | |
| SCHEMBL20890503 | 0.80 | CHRNA7 (0.61) | CHRNA7L3MBTL1HTR6ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8907097-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906925-B2 | Pyrido[4,3-B]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2346332-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | Medivation Technologies, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051218-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CHRNA7 72/4885L3MBTL1 2178/4885HTR6 13/4885 |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | CHRNA7 776/4885L3MBTL1 1436/4885HTR6 1200/4885 |
| US-20130190322-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CHRNA7 72/4885L3MBTL1 2178/4885HTR6 13/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CHRNA7 72/4885L3MBTL1 2178/4885HTR6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.